Bedeutung des C-reaktiven Proteins im Rahmen maligner ...

59
14. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory
response syndrome: what we do and do not know about cytokine regulation. Crit Care
Med 1996; 24:163-172
15. Brkovic D, Stähler G. Stadiengerechte chirurgische Therapie des Nierenzellkarzinoms.
Der Onkologe 1988;4:237-246
16. Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: a biomarker of
survival in patients with metastatic renal cell carcinomas treated with subcutaneous
interleukin-2 based immunotherapy. J Urol 2005;173:52-55
17. Chan DY, Marshall FF. Surgery in advanced and metastatic renal cell carcinoma. Cur
Op in Urol 1998;8:369-373
18. Cheville JC, Lohse CM, Zinck H, Weaver A, Blute ML. Comparisons of outcome and
prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg
Pathol 2003;27:612-624
19. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF,
Stein H, Mason DY. Immunoenzymatic labeling of monoklonal antibodies using
immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase
(APAAP complexes). J Histochem Cytochem 1984;32:219-229
20. De Beer FC, Hind CR, Fox KM, et al. Measurementof serum C-reactive protein
concentration in myocardial ischaemia and infarction. Br Heart J 1982;47:239-243
21. Du Clos TW, Zlock LT, Rubin RL. Analysis of the binding of C-reactive protein to
histones and chromatin. J Immunol 1988;141:4266-4270
22. Earlam S, Glover C, Fordy C ET AL: Relation between tumour size, quality of life, and
survival in patients with colorectal liver metastases. J Clin Oncol 1996;14:171-175
23. Erlinger TP, Platz EA, Nader R, Helzlsouer KJ. C-reactive protein and the risk of
incident colorectal cancer. Jama 2004;291:585-590
24. Flanigan RC, Blumenstein BA, Salmon S, Crawford E. Cytoreduction Nephrectomy in
metastatic renal cancer: results of Southwest Oncology group trial 8949. Proc Am Soc
Clin Oncol 2000;19:3.2a
25. Fujikawa K, Matsui Y, Oka H et al. Serum C-reactive protein level and the impact of
cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol
1999;162:1934-1937
26. Fujikawa K, Matsui Y, Miura K, Kobayashi T, Oka H, Fukuzawa S, Takeuchi H. Serum
immunosupressive acidic protein and natural killer cell activity in patients with
metastatic renal cell carcinoma before and after nephrectomy. J Urol 2000;164:673-675
27. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to
inflammation. N Engl J Med 1999;340:448-454